Nuvelo to be Featured at the Third Annual JMP Securities Research Conference
March 04 2004 - 9:00AM
PR Newswire (US)
Nuvelo to be Featured at the Third Annual JMP Securities Research
Conference SUNNYVALE, Calif., March 4 /PRNewswire-FirstCall/ --
Nuvelo, Inc. (Nasdaq: NUVO; interim ticker symbol: NUVOD) today
announced that Ted W. Love, M.D., president and CEO, will be
presenting at the Third Annual JMP Securities Research Conference
in San Francisco, California, on Tuesday, March 9, 2004 at 2:50
p.m. Pacific Time. Dr. Love will provide a brief corporate overview
and discuss the company's recently expanded pipeline and near-term
milestones. A live audio webcast of the presentation will be
available online via the Investor Relations portion of Nuvelo's Web
site at http://www.nuvelo.com/ or at
http://w.on24.com/r.htm?e=5221&s=1&k=A588DCA3E7E830DE49B14E0B4B4A2811
. About Nuvelo Nuvelo, Inc. is engaged in the discovery,
development and commercialization of life improving therapeutics
for the treatment of human disease. Nuvelo's lead product
candidate, alfimeprase, is partnered with Amgen and is currently in
two Phase 2 trials in two indications, peripheral arterial
occlusion and catheter occlusion. Additional programs include
cardiovascular product candidates ARC183 and rNAPc2 and drug
discovery focused on antibody targets and secreted proteins.
Information about Nuvelo is available at our new Web site at
http://www.nuvelo.com/ or by phoning 408-215-4000. DATASOURCE:
Nuvelo, Inc. CONTACT: Pete Garcia, Sr. VP and Chief Financial
Officer, +1-408-215-4574, or , or Nicole Estrin, Manager of
Corporate Communications & IR, +1-408-215-4572, or , both of
Nuvelo, Inc. Web site: http://www.nuvelo.com/
Copyright